ArticleAntibiotics (Basel, Switzerland)2026
A National Collaborative Project to Decrease Healthcare-Associated Infections in Intensive Care Units: Results from Stop Hospital Infection, in Portugal.
Article in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThe collaborative "Stop Hospital Infection 2.0", implemented in Portugal between 2023 and 2025, aimed to reduce the incidence of catheter-associated urinary tract infection (CAUTI), ventilator-associated pneumonia (VAP) and central-line associated bloodstream infection (CLABSI) by 50.0% in 21 hospitals.
methodsThe project followed the Breakthrough Series methodology. Each team was to audit the national preventive bundles, using a Kamishibai card, and drive changes using plan-do-study-act cycles. Before the project, teams reported their 6-month baseline incidence levels. The main outcome was the incidence of infection. The secondary outcome was the proportion of teams that achieved a ≥50.0% reduction in incidence. The number of infections, deaths and bed-days potentially prevented, and costs saved during the project were estimated, along with the potential gains in the future.
resultsIncidence rate for teams reporting at least 36 months decreased 47.6% in CAUTI (4.8 to 2.5 infections/1000 device-days), 66.1% in CLABSI (1.5 to 0.5 infections/1000 device-days) and 50.0% in VAP (9.9 to 5.0 infections/1000 intubation-days). The proportion of teams achieving a reduction of at least 50% in infection incidence was 60.0%, 100% and 57.1%, respectively. Teams reporting ≥24 months may have prevented 465 HAI, 108 deaths, 4526 bed-days and saved 8,375,841 euros. In the future, the teams who reported for at least 36 months may avoid 150 cases, 36 deaths, 1538 bed-days and 2,693,546 euros, yearly.
conclusionsA national collaborative focused on evidence-based bundles may be effective in decreasing the incidence of CAUTI, CLABSI and VAP in adult intensive care units.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.